View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 20, 2020updated 27 Nov 2020 1:45pm

Boehringer and Icahn School begin enrolment in Covid-19 trial

The Icahn School of Medicine at Mount Sinai, Department of Medicine's Clinical Trials Office and Boehringer Ingelheim have enrolled the first patient to evaluate nintedanib in adult patients with acute lung injury following Covid-19 infection.

The Icahn School of Medicine at Mount Sinai, Department of Medicine’s Clinical Trials Office and Boehringer Ingelheim have enrolled the first patient to evaluate nintedanib in adult patients with acute lung injury following Covid-19 infection.

Nintedanib is a tyrosine kinase inhibitor that targets receptors involved in signalling pathways that lead to pulmonary fibrosis.

Named Early Nintedanib Deployment in Covid-19 Interstitial Fibrosis ENDCOV-I (ENDCOV-I), the trial will be conducted at the Icahn School of Medicine on 120 patients.

The randomised, double-blinded, placebo-controlled study will analyse the development and course of pulmonary fibrosis in patients who are administered nintedanib or placebo and who need invasive or non-invasive respiratory support.

Percent change in forced vital capacity (FVC), a measurement of lung function, compared to baseline over 180 days will be the trial’s primary endpoint.

Secondary endpoints will be the change from baseline FVC at 90 days, death within 90 days and 180 days from enrolment due to respiratory or any cause.

Also, qualitative and quantitative change in chest CT fibrosis score graded by blinded chest radiologists will be analysed.

Icahn School of Medicine at Mount Sinai Advanced Lung & Interstitial Lung Disease Program director and trial primary investigator Maria Padilla said: “A significant percentage of Covid-19 patients with acute lung injury may develop lung fibrosis based on clinical observations.

“Our team of researchers and our partner Boehringer Ingelheim share a commitment to improving outcomes in this vulnerable patient population.”

Earlier this month, Boehringer Ingelheim announced positive results from interim analysis of the SENSCIS-ON trial evaluating nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena